Additionally, it was discovered that palbociclib, in combination with imatinib, has an additive effect on BCR-ABL and Ph-positive ALL cell lines.[31,41] Studies have demonstrated that palbociclib increases ALL cells’ sensitivity to imatinib, improving its effectiveness. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.